897666-34-1

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-[2-(4-fluorophenoxy)ethyl]-, 1,1-dimethylethyl ester
• CAS NO: 897666-34-1
• Molecular Formula: C18H26FNO3
• Molecular Weight: 323.408
• Mol File: 897666-34-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-[2-(4-fluorophenoxy)ethyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-[2-(4-fluorophenoxy)ethyl]-, 1,1-dimethylethyl ester(897666-34-1)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-[2-(4-fluorophenoxy)ethyl]-, 1,1-dimethylethyl ester(897666-34-1)

Safety Data

• Hazardous Substances Data: 897666-34-1(Hazardous Substances Data)

Upstream product

• 371-41-5 4-Fluorophenol 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 169457-73-2 tert-butyl 4-(2-bromoethyl)piperidine-1-carboxylate 

Downstream Products

• 141430-57-1 4-[2-(4-Fluoro-phenoxy)-ethyl]-piperidine Hydrochloride 
• 291289-20-8 4-(2-(4-fluorophenoxy)ethyl)piperidine 
• 952055-51-5 2-{4-[2-(4-Fluoro-phenoxy)-ethyl]-piperidin-1-ylmethyl}-1-methyl-1H-benzoimidazole 

Relevant articles and documents

Synthesis of arrays using low molecular weight MPEG-assisted mitsunobu reaction

Triphenylphosphine tagged with a short poly(ethyleneglycol)-ω- monomethyl ether chain (light MPEG, 10-16 ethylenoxy units, MTPP-G2) and an MPEG-tagged version of diethyl azodicarboxylate (MDEAD) have been used to prepare a 20 member library of esters, ethers, and sulfonamides, with cLogP?s in the range of 1.4-5.7 on a 0.1 mmol scale. Removal of MPEG-tagged side products was achieved by MPEG-assisted solid-phase extraction (MSPE) on prepacked silica columns to give the products in good yield and high purity.

Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators

The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.